Smith Group Asset Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | $50.9M | Buy |
982,751
+44,726
| +5% | +$2.32M | 2.69% | 6 |
|
|
2021
Q4 | $55.4M | Buy |
938,025
+494,205
| +111% | +$24.5M | 2.54% | 10 |
|
|
2021
Q3 | $19.1M | Hold |
443,820
| – | – | 0.97% | 37 |
|
|
2021
Q2 | $17.4M | Buy |
443,820
+443,500
| +138,594% | +$17.2M | 0.85% | 38 |
|
|
2021
Q1 | $12K | Buy |
320
+109
| +52% | +$3.87K | ﹤0.01% | 246 |
|
|
2020
Q4 | $8K | Sell |
211
-11
| -5% | -$403 | ﹤0.01% | 290 |
|
|
2020
Q3 | $8K | Hold |
222
| – | – | ﹤0.01% | 287 |
|
|
2020
Q2 | $7K | Hold |
222
| – | – | ﹤0.01% | 283 |
|
|
2020
Q1 | $7K | Hold |
222
| – | – | ﹤0.01% | 333 |
|
|
2019
Q4 | $8K | Hold |
222
| – | – | ﹤0.01% | 357 |
|
|
2019
Q3 | $7K | Buy |
222
+122
| +122% | +$4.44K | ﹤0.01% | 369 |
|
|
2019
Q2 | $4K | Hold |
100
| – | – | ﹤0.01% | 388 |
|
|
2019
Q1 | $4K | Hold |
100
| – | – | ﹤0.01% | 432 |
|
|
2018
Q4 | $4K | Hold |
100
| – | – | ﹤0.01% | 425 |
|
|
2018
Q3 | $4K | Hold |
100
| – | – | ﹤0.01% | 414 |
|
|
2018
Q2 | $3K | Hold |
100
| – | – | ﹤0.01% | 413 |
|
|
2018
Q1 | $3K | Hold |
100
| – | – | ﹤0.01% | 429 |
|
|
2017
Q4 | $3K | Buy |
100
+18
| +22% | +$614 | ﹤0.01% | 432 |
|
|
2017
Q3 | $3K | Hold |
82
| – | – | ﹤0.01% | 439 |
|
|
2017
Q2 | $3K | Sell |
82
-127
| -61% | -$4K | ﹤0.01% | 439 |
|
|
2017
Q1 | $7K | Buy |
209
+127
| +155% | +$4K | ﹤0.01% | 435 |
|
|
2016
Q4 | $7K | Sell |
82
-127
| -61% | -$3.88K | ﹤0.01% | 436 |
|
|
2016
Q3 | $7K | Buy |
209
+127
| +155% | +$4.25K | ﹤0.01% | 421 |
|
|
2016
Q2 | $3K | Hold |
82
| – | – | ﹤0.01% | 461 |
|
|
2016
Q1 | $2K | Sell |
82
-54
| -40% | -$1.54K | ﹤0.01% | 437 |
|
|
2015
Q4 | $4K | Hold |
136
| – | – | ﹤0.01% | 443 |
|
|
2015
Q3 | $4K | Hold |
136
| – | – | ﹤0.01% | 374 |
|
|
2015
Q2 | $4K | Hold |
136
| – | – | ﹤0.01% | 364 |
|
|
2015
Q1 | $4K | Hold |
136
| – | – | ﹤0.01% | 380 |
|
|
2014
Q4 | $4K | Sell |
136
-739
| -84% | -$21.2K | ﹤0.01% | 391 |
|
|
2014
Q3 | $25K | Buy |
875
+658
| +303% | +$18.5K | ﹤0.01% | 293 |
|
|
2014
Q2 | $6K | Hold |
217
| – | – | ﹤0.01% | 361 |
|
|
2014
Q1 | $7K | Sell |
217
-41
| -16% | -$1.22K | ﹤0.01% | 351 |
|
|
2013
Q4 | $8K | Sell |
258
-149
| -37% | -$4.34K | ﹤0.01% | 335 |
|
|
2013
Q3 | $11K | Buy |
+407
| New | +$11.1K | ﹤0.01% | 328 |
|
Other funds holding PFE
Smith Group Asset Management's PFE Position: Q1 2022 in Review
Smith Group Asset Management increased its Pfizer (PFE) stake by 4.8% in Q1 2022, buying an estimated $2.32M and bringing the position to 982,751 shares worth $50.9M. The position accounts for 2.69% of the portfolio, ranked #6.
Smith Group Asset Management first reported a position in PFE in Q3 2013 and has held it in 35 quarters since. The position peaked at $55.4M in Q4 2021. 3,195 funds tracked by Wall St. Rank hold PFE as of Q1 2022.
- Smith Group Asset Management held 982,751 shares of Pfizer worth $50.9M as of Q1 2022.
- Smith Group Asset Management bought 44,726 Pfizer shares in Q1 2022, an estimated $2.32M.
- Pfizer made up 2.69% of Smith Group Asset Management's portfolio in Q1 2022, its #6 holding.
- Smith Group Asset Management first reported a position in Pfizer in Q3 2013 and has held it in 35 quarters since.
- Smith Group Asset Management's Pfizer position peaked at $55.4M in Q4 2021.
- 3,195 funds tracked by Wall St. Rank held Pfizer as of Q1 2022.
Based on Smith Group Asset Management's 13F filing for Q1 2022, filed 5 May 2022.